Looking into the technicals, CorMedix, Inc. (NYSE:CRMD) has scored 88% Buy indication. The stock is also flashing a Buy from the Barchart TrendSpotter trading system. Traders hoping to speculate on the CRMD’s short-term trajectory should know that short terms indicators for the stock averaged 100% Buy with an average daily trading volume over the past 20 days at 2946730 shares. CRMD stock has overall a 0.5% Buy signal considering medium term indicators and the 50-day average daily volume remained almost 2668974 shares. It’s also worth noting that the stock, whose average daily volume over the 100 days prior to this writing was 3401959 shares, is 100% Buy on the basis of long term indicators.
The share price is currently staying around the first support level of $1.9. Below this, the next support is placed in the zone of $1.79. Till the time, the CRMD stock trades above this level, bulls have nothing to fear. On momentum oscillators front, ‘RSI’ has touched 65.8 on daily chart, which may remain a cause for concern. If the price breaks below $1.79 level on closing basis, then we may see more profit booking and the stock may show further weakness. On the flipside, hitting the $2.08 mark may result into a pull-back move towards $2.15 level.
CorMedix, Inc. (CRMD) is projected to climb by 136.32 percent over the next 12 months, according to price target estimates compiled by finviz. Meanwhile, they have set a $6price as 12-month high target. This represents a whopping 198.51 percent increase from where shares are trading today. The 12-month median price target assigned by the analysts stands at $4.75, which represents a return potential of 136.32 percent when compared to the closing price of the stock of $2.01 on Thursday, January 31. The lowest price target for the stock is $3.5 — slightly more than 74.13 percent from CRMD’s current share price.
Here’s a rundown of insider trading activity for sense of CorMedix, Inc. (NYSE:CRMD). The earliest insider trade took place on 12/20/2018. Khan Mehmood gathered a total of 100 thousand shares of company at average share price of $1.24. The total for the purchase was set at $124 thousand. After this transaction, the Director account balance stood at 564.58 thousand shares. The stock grew 51.61 percent since that insider purchase. On 12/20/2018, Lefkowitz Steven W, Director, purchased 20 thousand shares at a price per share of $1.18. This added 23.6 thousand shares to the insider’s fortune and the stock saw a 59.32 percent rally in value since the news became public. This transaction left 367.14 thousand shares in the Director account. On 12/14/2018, Director Kaplan Myron performed a purchase transaction worth $73.5 thousand. This purchase at $1.47 each has added 50 thousand shares into the insider’s portfolio position. Meanwhile, shares have recorded 27.89 percent increase since the transaction was reported. The insider now is left with 431.17 thousand shares remaining in the account. Armstrong Jr. John L., who performs the Exec VP of Tech Operations job, bought 250 thousand shares for $362.5 thousand. The acquisition occurred on 11/29/2018 was priced at $1.45 per share. The share price soared 29.66 percent since the reporting date. Armstrong Jr. John L. now left with a stake of 288.86 thousand CRMD stock worth $580.61 thousand after the insider buying.
CRMD shares accumulated 0.13 points or 6.91 percent on Thursday to $2.01 with a heavy trade volume of 2.85 million shares. After opening the session at $1.86, the shares went as high as $2.04 and as low as $1.86, the range within which the stock’s price traded throughout the day. The firm is left with a market cap of $215 million and now has 107.13 million shares outstanding. CorMedix, Inc. (CRMD) stock has gained 55.81 percent of market value in 21 trading days.
Analysts at ROTH Capital, assumed coverage of CorMedix, Inc. (NYSE:CRMD) with Buy recommendation, according to their opinion released on December 06. H.C. Wainwright analysts again handed out a Buy rating to CRMD stock but they lifted target price for the shares in a flash note to investors on September 25. The price target has been raised from $3 to $4. H.C. Wainwright, analysts launched coverage of CRMD stock with a Buy rating, according to their flash note to investors on September 25. Analysts at Rodman & Renshaw are sticking to their Buy recommendation. However, on August 10, they lifted target price for these shares to $3 from $5. Analysts at Rodman & Renshaw, made their first call for the stock with a Buy rating, according to a research note that dated back to August 10.
CRMD stock has a trailing 3-year beta of 2.71, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was -$0.5 a share in the trailing twelve months. The stock’s value has surged 55.81 percent year to date (YTD) against a rise of 328.75 percent in 12 month’s time. The company’s shares still trade -16.25 percent away from its 1-year high of $2.40 and 1067.93 percent up from 52-week low of $0.17. The average consensus rating on the company is 2, on a scale where 5 equates to a unanimous sell rating. In short, the mean analyst recommendations are calling this stock a buy.
Shares of CorMedix, Inc. (CRMD) are trading at a P/E ratio of 0 times earnings reported for the past 12 months. The industry CRMD operates in has an average P/E of 29.45. Its P/E ratio went as low as 0X and as high as 0 over the 5-year span. Further, it is sporting a 430.66 on the Price-to-Sales ratio. Compare this with the industry average P/S of 19.89. 37.2 percent is the gross profit margin for CorMedix, Inc. and operating margin sits at 0 percent. Along with this, the net profit margin is 0 percent.
CRMD will be declaring its Q4 financial results on March 14. Analysts are forecasting revenue to climb 166.7 percent to $240M in the next fiscal quarter, while earnings are seen soaring by nearly -46.67 percent to -$0.08 per share. History has shown that shares in CorMedix, Inc. have gone down on 12 different earnings reaction days and are predicted to add 0.08 percent when the company reports upcoming earnings. In last reported earnings results, it earned -$0.11 per share, worse than the -$0.06, adjusted, expected by Thomson Reuters consensus estimate. Revenue was $120000, worse than the $140000 analysts expected. Earnings are estimated to increase by 7.8 percent this year, 35.7 percent next year and continue to increase by 0 percent annually for the next 5 years.